- p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situMing Yin
Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA
Hum Pathol 39:527-35. 2008..Alterations of 9p21/chromosome 9 detected by fluorescence in situ hybridization can also be used for diagnostic confirmation and prognostic prediction...
- Amylase α-1A (AMY1A): a novel immunohistochemical marker to differentiate chromophobe renal cell carcinoma from benign oncocytomaSarika Jain
Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA Department of Pathology, East Carolina University, Greenville, NC
Am J Surg Pathol 37:1824-30. 2013..95-1.00) and 90.74% (95% confidence interval, 0.80-0.97), respectively. These data show that the novel marker AMY1A can be of great diagnostic utility when trying to differentiate ChRCC (classic and eosinophilic variant) and oncocytoma. ..
- Prevalence of incidental prostate cancer in the general population: a study of healthy organ donorsMing Yin
Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
J Urol 179:892-5; discussion 895. 2008..We analyzed our data set of incidental prostate cancer, derived from a project accruing prostate tissues for research from normal organ donors, who are a predominantly white population...